Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Метаболический синдром, неалкогольная жировая болезнь печени и статины: кому, когда и как?
Метаболический синдром, неалкогольная жировая болезнь печени и статины: кому, когда и как?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. World Health Organization. Obesity and Overweight 2003.
2. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndromea new worldwide definition. Lancet 2005; 366: 1059–62.
3. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20.
4. Loria P, Lonardo A, Carulli L et al. Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 31–6.
5. Schreuder TCMA, Verwer BJ, van Nieuwkerk CMJ, Mulder CJJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment; World J Gastroenterol 2008; 14 (16): 2474–86.
6. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis 2007; 17: 125–39.
7. Bergman RN, Kim SP, Catalano KJ et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006; 14 (Suppl. 1): 16S–19S.
8. Chavez-Tapia NC, Mendez-Sanchez N, Uribe M. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2006; 144: 379; author reply 380.
9. Hae Jin Kim, Hyeong Jin Kim, Kwang Eun Lee et al. Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese, Nondiabetic Adults. Arch Intern Med 2004; 164 (19): 2169–75.
10. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 15, 143 (10): 722–8.
11. Ezquerra EA, Vázquez JMC, Barrero AA. Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. Departamento de Cardiología, Clínica Universitaria de Navarra, Pamplona, Navarra, Spain.
12. Raszeja-Wyszomirska J, Lawniczak M, Marlicz W et al. Non-alcoholic fatty liver disease – new view. Pol Merkur Lekarski 2008; 24 (144): 568–71.
13. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease; Diabet Med 2005; 22 (9): 1129–33.
14. Kivici M, Gulten M, Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17 (7): 13–8.
15. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15 (11): 2792–800.
16. Ryuichi K, Hitomi T, Nobuyuki O et al. Metabolic syndrome, diabetes and subclinical atherosclerosis as assessed by carotid intima-media thickness. J Atheroscler Thromb. Vol. 14 (2).
17. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokin 1997; 32 (5): 403–25.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
19. Naga Chalasani, Sidharth S. Bhardwaj, Lipid Lowering Agents That Cause Drug-Induced Hepatotoxicity. Clin Liver Dis 2007; 11 (3): 597–vii.
20. Horsman Y, Desager JP, Harvengt C. biochemical changes and morphological alterations of the liver in guinea-pigs after administration of Simvastatin. Pharmacol Toxicol 1990; 67: 336–9.
21. de Denus S, Sprinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmocotherapy 2004; 24: 584–91.
22. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287–92.
23. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2008.
24. Mattias Т Ekstedt, Lennart EТ Franzén, Ulrik LТ Mathiesen et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes. Histopathological Follow-Up Study 2007; 47 (1): 135–41.
25. Naga Chalasani, Statins and Hepatotoxicity: Focus on Patients with Fatty Liver. Hepatology 2005; 41 (4).
26. Dominguez EG, Gisbert JP et al. A pilot study of atorvastatin treatment in dyslipidemia, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643–7.
2. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndromea new worldwide definition. Lancet 2005; 366: 1059–62.
3. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20.
4. Loria P, Lonardo A, Carulli L et al. Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 31–6.
5. Schreuder TCMA, Verwer BJ, van Nieuwkerk CMJ, Mulder CJJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment; World J Gastroenterol 2008; 14 (16): 2474–86.
6. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis 2007; 17: 125–39.
7. Bergman RN, Kim SP, Catalano KJ et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006; 14 (Suppl. 1): 16S–19S.
8. Chavez-Tapia NC, Mendez-Sanchez N, Uribe M. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2006; 144: 379; author reply 380.
9. Hae Jin Kim, Hyeong Jin Kim, Kwang Eun Lee et al. Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese, Nondiabetic Adults. Arch Intern Med 2004; 164 (19): 2169–75.
10. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 15, 143 (10): 722–8.
11. Ezquerra EA, Vázquez JMC, Barrero AA. Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. Departamento de Cardiología, Clínica Universitaria de Navarra, Pamplona, Navarra, Spain.
12. Raszeja-Wyszomirska J, Lawniczak M, Marlicz W et al. Non-alcoholic fatty liver disease – new view. Pol Merkur Lekarski 2008; 24 (144): 568–71.
13. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease; Diabet Med 2005; 22 (9): 1129–33.
14. Kivici M, Gulten M, Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17 (7): 13–8.
15. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15 (11): 2792–800.
16. Ryuichi K, Hitomi T, Nobuyuki O et al. Metabolic syndrome, diabetes and subclinical atherosclerosis as assessed by carotid intima-media thickness. J Atheroscler Thromb. Vol. 14 (2).
17. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokin 1997; 32 (5): 403–25.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
19. Naga Chalasani, Sidharth S. Bhardwaj, Lipid Lowering Agents That Cause Drug-Induced Hepatotoxicity. Clin Liver Dis 2007; 11 (3): 597–vii.
20. Horsman Y, Desager JP, Harvengt C. biochemical changes and morphological alterations of the liver in guinea-pigs after administration of Simvastatin. Pharmacol Toxicol 1990; 67: 336–9.
21. de Denus S, Sprinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmocotherapy 2004; 24: 584–91.
22. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287–92.
23. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2008.
24. Mattias Т Ekstedt, Lennart EТ Franzén, Ulrik LТ Mathiesen et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes. Histopathological Follow-Up Study 2007; 47 (1): 135–41.
25. Naga Chalasani, Statins and Hepatotoxicity: Focus on Patients with Fatty Liver. Hepatology 2005; 41 (4).
26. Dominguez EG, Gisbert JP et al. A pilot study of atorvastatin treatment in dyslipidemia, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643–7.
Авторы
О.М.Драпкина, М.В.Костюкевич
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.